Leronlimab binds to CCR5 100% Leronlimab reduces
Post# of 148264
Leronlimab reduces deaths by 24% vs SOC in critical covid-19 patients
Leronlimab reduces deaths by 31.8% vs SOC in critical covid-19 patients 65 or younger
After discussions with the FDA & Amarex about an EUA, Cytodyn applied for Leronlimab's first EUA for covid-19 patients on March 12th.
There are no approved available drugs that doctors can give to critical covid-19 patients and then tell relatives that the outlook for the patient to survive is good.
About 1000 Americans continue to die each day from covid-19, all critical condition at time of death, leronlimab can save between 240 to 320 of these folks, we know it, the FDA knows it, the FDA has our EUA application as of 10 days ago. Tomorrow, about another 300 could have lived but will die. FDA: "We'll think about it....."